The combination of bevacizumab (Avastin) and interferon-alpha (Roferon-A) as first-line treatment in patients with metastatic renal cell carcinoma offers significant improvement in progression-free survival compared with interferon-alpha alone, according to a study published in The Lancet (2007; 370:2103-11).
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.